rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Drug Discovery in Japan
    sub title: Investigating the Sources of Innovation
  name:
    name part: Nagaoka, Sadao.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: si
    date issued: 2019
    edition: 1st ed. 2019.
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: XV, 333 p. 57 illus., 33 illus. in color. online resource.
  abstract: This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibitor, the scientific discovery for which a 2018 Nobel Prize in Physiology or Medicine was awarded to Prof. Tasuku Honjo, Kyoto University. The book shows the pervasive high uncertainty in drug discovery: frequent occurrences of unexpected difficulties, discontinuations, serendipities, and good luck, significantly because drug discovery starts when the underlying science is incomplete. Thus, there exist dynamic interactions between scientific progress and drug discovery. High uncertainty also makes the value of an entrepreneurial scientist high. Such scientists fill the knowledge gaps by absorbing external scientific progress and by relentless pursuit of possibilities through their own research, often including unauthorized research, to overcome crises. Further, high uncertainty and its resolution significantly characterize the evolution of competition in the drug industry. The patent system promotes innovation under high uncertainty not only by enhancing appropriability of R&D investment but also by facilitating the combination of knowledge and capabilities among different firms through disclosure. Understanding such a process significantly benefits the creation of innovation management and policy practices.
  table of contents: Foreword -- Acknowledgement -- Chapter 1: Introduction -- Chapter 2: Compactin -- Chapter 3: Pravastatin (Pravachol, Mevalotin) -- Chapter 4: Rosuvastatin(Crestor) -- Chapter 5: Leuprorelin (Leuplin, Lupron, Viadur) -- Chapter 6: Oflaxacin and levofloxacin (Tarivid/Cravit) -- Chapter 7: Tamsulosin (Harnal, Flomax, OMNIC) -- Chapter 8: Pranlukast (Onon) -- Chapter 9: Tacrolimus (Prograf) -- Chapter 10: Pioglitazone (Actos, Glustin) -- Chapter 11: Donepezil (Aricept) -- Chapter 12: Candesartan (Blopress, Atacand) -- Chapter 13: Tocilizumab (Actemra,Ro-actemra) -- Chapter 14: Nivolumab (Opdivo) -- Chapter 15: Sources of innovation of drug discovery in Japan and its implications.
  note: edited by Sadao Nagaoka.
  subject:
    topic: Economic policy
  subject:
    topic: Management
  subject:
    topic: Industrial management
  subject:
    topic: Japan-History
  subject:
    topic: R & D/Technology Policy
  subject:
    topic: Innovation/Technology Management
  subject:
    topic: History of Japan
  classification: JF20-2112
  classification: 338.926
  related item:
    title info:
      title: Springer eBooks
  identifier: 9789811389061
  identifier: https://doi.org/10.1007/978-981-13-8906-1
  record info:
    record creation date: 191024
    record change date: 20191028101105.0
    record identifier: 978-981-13-8906-1